News Column

Findings from Institute Pasteur Update Knowledge of Rabies

January 29, 2014



By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Investigators publish new report on Rhabdoviridae Infections. According to news reporting out of Tunis, Tunisia, by NewsRx editors, research stated, "Human and equine rabies immunoglobulins are currently available for passive immunization against rabies. However, these are hampered by the limited supply and some drawbacks."

Our news journalists obtained a quote from the research from Institute Pasteur, "Advances in antibody engineering have led to overcome issues of clinical applications and to improve the protective efficacy. In the present study, we report the generation of a trivalent single-chain Fv (scFv50AD1-Fd), that recognizes the rabies virus glycoprotein, genetically fused to the trimerization domain of the bacteriophage T4 fibritin, termed 'foldon' (Fd). scFv50AD1-Fd was expressed as soluble recombinant protein in bacterial periplasmic space and purified through affinity chromatography. The molecular integrity and stability were analyzed by polyacrylamide gradient-gel electrophoresis, size-exclusion chromatography and incubation in human sera. The antigen-binding properties of the trimeric scFv were analyzed by direct and competitive-ELISA. Its apparent affinity constant was estimated at 1.4 +/- 0.25 x 10(9) M-1 and was 75-fold higher than its monovalent scFv (1.9 +/- 0.68 x 10(7) M-1). The scFv50AD1-Fd neutralized rabies virus in a standard in vitro and in vivo neutralization assay. We showed a high neutralization activity up to 75-fold compared with monovalent format and the WHO standard serum. The gain in avidity resulting from multivalency along with an improved biological activity makes the trivalent scFv50AD1-Fd construct an important reagent for rabies protection."

According to the news editors, the research concluded: "The antibody engineering approach presented here may serve as a strategy for designing a new generation of anti-rabies for passive immunotherapy."

For more information on this research see: Engineering of a recombinant trivalent single-chain variable fragment antibody directed against rabies virus glycoprotein G with improved neutralizing potency. Molecular Immunology, 2014;57(2):66-73. Molecular Immunology can be contacted at: Pergamon-Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. (Elsevier - www.elsevier.com; Molecular Immunology - www.elsevier.com/wps/product/cws_home/253)

Our news journalists report that additional information may be obtained by contacting I. Turki, Inst Pasteur Tunis, Lab Epidemiol & Microbiol Vet, Unite Specialisee Rage, Tunis 1002, Tunisia. Additional authors for this research include A. Hammami, H. Kharmachi and M. Mousli (see also Rhabdoviridae Infections).

Keywords for this news article include: Antibodies, Africa, Rabies, Tunisia, Virology, Immunology, Engineering, RNA Viruses, Glycoproteins, Immunotherapy, Blood Proteins, Glycoconjugates, Immunoglobulins, Immunomodulation, Rhabdoviridae Infections, Mononegavirales Infections

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Immunotherapy Weekly


Story Tools